[Opportunities for prostate-specific membrane antigen hybrid imaging in prostate cancer].

Abstract

Prostate-specific membrane antigen (PSMA) hybrid imaging is a promising new technique gaining importance in the field of prostate cancer (PCa) diagnosis and treatment planning. By combining PSMA radioligands and computed tomography (CT) or magnetic resonance imaging (MRI), PSMA hybrid imaging opens up new diagnostic opportunities. PSMA-PET/CT (PET: positron-emission tomography) is already well established in high-risk PCa for primary staging and tumor localization when biochemical recurrence occurs. Further potential indications for PSMA-PET/CT include tumor detection in the initial work-up before a rebiopsy with improved accuracy, the identification of target structures for precise local treatment in recurrent PCa (salvage radiotherapy or radio-guided surgery) as well as a prediction of response to PSMA radioligand therapy. This narrative review is based on a recent literature search and aims to highlight the opportunities of PSMA imaging in different disease stages of PCa.

• Authors: Anna-Sophie Strauß, Christian Bolenz, Ambros J Beer, Friedemann Zengerling, Meinrad Beer, Jonathan Miksch
• Journal: Urologie (Heidelberg, Germany) (Urologie) Vol. 62 Issue 11 Pg. 1153-1159 (Nov 2023) ISSN: 2731-7072 [Electronic] Germany
• Vernacular Title: Chancen der PSMA(prostataspezifisches Membranantigen)-Hybridbildgebung beim Prostatakarzinom.
• PMID: 37702749 (Publication Type: English Abstract, Journal Article, Review)
• Copyright: © 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Chemical References

• Prostate-Specific Antigen

Topics

• Male
• Humans
• Prostate (pathology)
• Positron Emission Tomography Computed Tomography (methods)
• Prostatic Neoplasms (pathology)
• Prostate-Specific Antigen
• Positron-Emission Tomography